We generated Melan-A specific CTL lines from the blood of HLA-A2 melanoma patients, according to a procedure already described12 and currently used to produce melanoma-specific CTL in a clinical trial (ClinicalTrials.gov Identifier: NCT02424916). This evidence concerns the gene MLANA and melanoma.